We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in our Advanced Prostate Cancer. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

Journal Scan / Research · November 29, 2022

AR-V7 Positivity as a Biomarker in Patients With mCRPC Treated With Cabazitaxel

European Journal of Cancer

 

Additional Info

European Journal of Cancer
CABA-V7: a prospective biomarker selected trial of cabazitaxel treatment in AR-V7 positive prostate cancer patients
Eur. J. Cancer 2022 Oct 06;177(2022)33-44, KT Isebia, B Mostert, BPS Belderbos, SAJ Buck, JCA Helmijr, J Kraan, CM Beaufort, MN Van, E Oomen-de Hoop, AM Sieuwerts, WFJ van IJcken, MCGN van den Hout-van Vroonhoven, RWW Brouwer, E Oole, P Hamberg, BCM Haberkorn, HH Helgason, R de Wit, S Sleijfer, RHJ Mathijssen, JWM Martens, MPHM Jansen, J van Riet, MP Lolkema

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading